Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis - 12/10/16

Doi : 10.1016/S1470-2045(16)30240-6

Puya Gharahkhani, DrPhD ^a,^{^{*
Contributed equally}}^⁎ , Rebecca C Fitzgerald, MD ^c,^{^{*
Contributed equally}}, Thomas L Vaughan, MD ^d,^{^{*
Contributed equally}}, Claire Palles, PhD ^e,^{^{*
Contributed equally}}, Ines Gockel, ProfMD ^g,^{^{*
Contributed equally}}, Ian Tomlinson, MD ^e,^{^{*
Contributed equally}}, Matthew F Buas, PhD ^d, Andrea May, MD ^h, Christian Gerges, MD ⁱ, Mario Anders, ProfMD ^j,^k, Jessica Becker, PhD ^l, Nicole Kreuser, BSc ^g, Tania Noder, BN ^j, Marino Venerito, MD ^m, Lothar Veits, MD ⁿ, Thomas Schmidt, MD ^o, Hendrik Manner, MD ^p, Claudia Schmidt, MD ^q, Timo Hess, MSc ^l, Anne C Böhmer, PhD ^l, Jakob R Izbicki, ProfPhD ^r, Arnulf H Hölscher, ProfMD ^q, Hauke Lang, ProfMD ^s, Dietmar Lorenz, MD ^t, Brigitte Schumacher, MD ^i,^u, Andreas Hackelsberger, MD ^v, Rupert Mayershofer, MD ^w, Oliver Pech, MD ^x, Yogesh Vashist, MD ^r,^y, Katja Ott, MD ^o,^z, Michael Vieth, MD ⁿ, Josef Weismüller, MD ^aa, Markus M Nöthen, ProfMD ^l, the
Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON)^{^†}
Directed the work jointly
, ^{^{‡
Consortium members listed in Supplementary Material}}
the
Esophageal Adenocarcinoma GenEtics Consortium (EAGLE)^{^‡}
Consortium members listed in Supplementary Material

the
Wellcome Trust Case Control Consortium 2 (WTCCC2)^{^‡}
Consortium members listed in Supplementary Material

Stephen Attwood, MD ^ab, Hugh Barr, MD ^ac, Laura Chegwidden, MSc ^ad, John de Caestecker, MD ^ae, Rebecca Harrison, MD ^af, Sharon B Love, MSc ^f, David MacDonald, DDS ^ag, Paul Moayyedi, MD ^ah, Hans Prenen, MD ^ai, R G Peter Watson, MD ^aj, Prasad G Iyer, MD ^ak, Lesley A Anderson, PhD ^al, Leslie Bernstein, PhD ^am, Wong-Ho Chow, PhD ^an, Laura J Hardie, PhD ^ao, Jesper Lagergren, ProfPhD ^ap,^ar, Geoffrey Liu, MD ^as, Harvey A Risch, MD ^at, Anna H Wu, PhD ^au, Weimin Ye, ProfPhD ^aq, Nigel C Bird, MD ^av, Nicholas J Shaheen, MD ^aw, Marilie D Gammon, PhD ^ax, Douglas A Corley, MD ^ay, Carlos Caldas, PhD ^az, Susanne Moebus, ProfPhD ^ba, Michael Knapp, PhD ^bb, Wilbert H M Peters, MD ^bc, Horst Neuhaus, MD ⁱ, Thomas Rösch, ProfMD ^j, Christian Ell, MD ^h, Stuart MacGregor, PhD ^a,^{^{†
Directed the work jointly}}, Paul Pharoah, PhD ^bd,^{^{†
Directed the work jointly}}, David C Whiteman, ProfMD ^b,^{^{†
Directed the work jointly}}, Janusz Jankowski, ProfMD ^be,^bf,^{^{†
Directed the work jointly}}, Johannes Schumacher, MD ^l,^{^{†
Directed the work jointly}}

^a Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

^b Cancer Control, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

^c Medical Research Council (MRC) Cancer Unit, Hutchison-MRC Research Centre and University of Cambridge, Cambridge, UK

^d Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

^e Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK

^f Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK

^g Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig, Leipzig, Germany

^h Department of Medicine II, Sana Klinikum, Offenbach, Germany

ⁱ Department of Internal Medicine, Evangelisches Krankenhaus, Düsseldorf, Germany

^j Department of Interdisciplinary Endoscopy, University Hospital Hamburg-Eppendorf, Hamburg, Germany

^k Department of Gastroenterology and Interdisciplinary Endoscopy, Vivantes Wenckebach-Klinikum, Berlin, Germany

^l Institute of Human Genetics, and Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany

^m Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany

ⁿ Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany

^o Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany

^p Department of Internal Medicine II, Horst Schmidt Kliniken Hospital, Wiesbaden, Germany

^q Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany

^r Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany

^s Department of General, Visceral and Transplant Surgery, University Medical Center, University of Mainz, Mainz, Germany

^t Department of General and Visceral Surgery, Sana Klinikum, Offenbach, Germany

^u Department of Internal Medicine and Gastroenterology, Elisabeth Hospital, Essen, Germany

^v Gastropraxis, Wiesbaden, Germany

^w Gastroenterologie am Burgweiher, Bonn, Germany

^x Department of Gastroenterology and Interventional Endoscopy, St John of God Hospital, Regensburg, Germany

^y Department of Visceral Surgery, Kantonsspital Aarau AG, Aarau, Switzerland

^z Department of General, Visceral and Thorax Surgery, RoMed Klinikum Rosenheim, Rosenheim, Germany

^aa Gastroenterologische Gemeinschaftspraxis, Koblenz, Germany

^ab Centre For Integrated Health Care Research, Durham University, Durham, UK

^ac Gloucestershire Royal Hospital, Gloucester, UK

^ad Plymouth University Peninsula School of Medicine and Dentistry, Plymouth, UK

^ae Digestive Diseases Centre, University Hospitals of Leicester, Leicester, UK

^af Department of Cellular Pathology, Leicester Royal Infirmary, Leicester, UK

^ag Department of Oral Biological and Medical Sciences, University of British Columbia, Vancouver, BC, Canada

^ah Department of Medicine, McMaster University, Hamilton, ON, Canada

^ai Department of Gastroenterology, University Hospitals Gasthuisberg, Leuven, Belgium

^aj Queen’s University Belfast, Centre of Medical Education, Royal Victoria Hospital, Belfast, UK

^ak Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

^al Centre for Public Health, Queen’s University Belfast, Belfast, UK

^am Department of Population Sciences, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, CA, USA

^an Department of Epidemiology, MD Anderson Cancer Center, Houston, TX, USA

^ao Division of Epidemiology, University of Leeds, Leeds, UK

^ap Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

^aq Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

^ar Division of Cancer Studies, King’s College London, London, UK

^as Pharmacogenomic Epidemiology, Ontario Cancer Institute, Toronto, ON, Canada

^at Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA

^au Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA

^av Department of Oncology, Medical School, University of Sheffield, Sheffield, UK

^aw Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA

^ax Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA

^ay Division of Research, and San Francisco Medical Center, Kaiser Permanente Northern California, Oakland, CA, USA

^az Department of Oncology, and Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK

^ba Centre of Urban Epidemiology, Institute of Medical Informatics, Biometry and Epidemiology, University of Essen, Essen, Germany

^bb Institute for Medical Biometry, Informatics, and Epidemiology, University of Bonn, Bonn, Germany

^bc Department of Gastroenterology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

^bd Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK

^be University of Central Lancashire, Westlakes Science and Technology Park, Moor Row, UK

^bf Warwick Medical School, University of Warwick, Warwick, UK

^* Correspondence to: Dr Puya Gharahkhani, Statistical Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia Correspondence to: Dr Puya Gharahkhani Statistical Genetics Laboratory QIMR Berghofer Medical Research Institute Brisbane QLD 4006 Australia

Summary

Background

Oesophageal adenocarcinoma represents one of the fastest rising cancers in high-income countries. Barrett’s oesophagus is the premalignant precursor of oesophageal adenocarcinoma. However, only a few patients with Barrett’s oesophagus develop adenocarcinoma, which complicates clinical management in the absence of valid predictors. Within an international consortium investigating the genetics of Barrett’s oesophagus and oesophageal adenocarcinoma, we aimed to identify novel genetic risk variants for the development of Barrett’s oesophagus and oesophageal adenocarcinoma.

Methods

We did a meta-analysis of all genome-wide association studies of Barrett’s oesophagus and oesophageal adenocarcinoma available in PubMed up to Feb 29, 2016; all patients were of European ancestry and disease was confirmed histopathologically. All participants were from four separate studies within Europe, North America, and Australia and were genotyped on high-density single nucleotide polymorphism (SNP) arrays. Meta-analysis was done with a fixed-effects inverse variance-weighting approach and with a standard genome-wide significance threshold (p<5 × 10⁻⁸). We also did an association analysis after reweighting of loci with an approach that investigates annotation enrichment among genome-wide significant loci. Furthermore, the entire dataset was analysed with bioinformatics approaches—including functional annotation databases and gene-based and pathway-based methods—to identify pathophysiologically relevant cellular mechanisms.

Findings

Our sample comprised 6167 patients with Barrett’s oesophagus and 4112 individuals with oesophageal adenocarcinoma, in addition to 17 159 representative controls from four genome-wide association studies in Europe, North America, and Australia. We identified eight new risk loci associated with either Barrett’s oesophagus or oesophageal adenocarcinoma, within or near the genes CFTR (rs17451754; p=4·8 × 10⁻¹⁰), MSRA (rs17749155; p=5·2 × 10⁻¹⁰), LINC00208 and BLK (rs10108511; p=2·1 × 10⁻⁹), KHDRBS2 (rs62423175; p=3·0 × 10⁻⁹), TPPP and CEP72 (rs9918259; p=3·2 × 10⁻⁹), TMOD1 (rs7852462; p=1·5 × 10⁻⁸), SATB2 (rs139606545; p=2·0 × 10⁻⁸), and HTR3C and ABCC5 (rs9823696; p=1·6 × 10⁻⁸). The locus identified near HTR3C and ABCC5 (rs9823696) was associated specifically with oesophageal adenocarcinoma (p=1·6 × 10⁻⁸) and was independent of Barrett’s oesophagus development (p=0·45). A ninth novel risk locus was identified within the gene LPA (rs12207195; posterior probability 0·925) after reweighting with significantly enriched annotations. The strongest disease pathways identified (p<10⁻⁶) belonged to muscle cell differentiation and to mesenchyme development and differentiation.

Interpretation

Our meta-analysis of genome-wide association studies doubled the number of known risk loci for Barrett’s oesophagus and oesophageal adenocarcinoma and revealed new insights into causes of these diseases. Furthermore, the specific association between oesophageal adenocarcinoma and the locus near HTR3C and ABCC5 might constitute a novel genetic marker for prediction of the transition from Barrett’s oesophagus to oesophageal adenocarcinoma. Fine-mapping and functional studies of new risk loci could lead to identification of key molecules in the development of Barrett’s oesophagus and oesophageal adenocarcinoma, which might encourage development of advanced prevention and intervention strategies.

Funding

US National Cancer Institute, US National Institutes of Health, National Health and Medical Research Council of Australia, Swedish Cancer Society, Medical Research Council UK, Cambridge NIHR Biomedical Research Centre, Cambridge Experimental Cancer Medicine Centre, Else Kröner Fresenius Stiftung, Wellcome Trust, Cancer Research UK, AstraZeneca UK, University Hospitals of Leicester, University of Oxford, Australian Research Council.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Methods

Study design and participants

Procedures

Statistical analysis

Role of the funding source

Results

Discussion

Export

Vol 17 - N° 10

P. 1363-1373 - octobre 2016 Retour au numéro

Article précédent

Paintfest America
Caroline Kinsey

| Article suivant

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L Kaufman, Jeffery Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P D’Angelo, Kent C Shih, Céleste Lebbé, Gerald P Linette, Michele Milella, Isaac Brownell, Karl D Lewis, Jochen H Lorch, Kevin Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis - 12/10/16

Summary

Background

Methods

Findings

Interpretation

Funding

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL